Abstract
Although de novo stage IV breast cancer is so far incurable, it has entered an era of individualized treatment and chronic disease management. Based on systemic treatment, whether the surgical resection of primary or metastatic foci of de novo stage IV breast cancer can bring survival benefits is currently controversial. We aimed to explore the clinicopathological factors and current status of the management of de novo stage IV breast cancer in China to provide a reference for clinical decisions. Based on the assistance of Chinese Society of Breast Surgery, a retrospective study was conducted to analyze the clinical data of patients with de novo stage IV breast cancer in 33 centers from January 2017 to December 2018. The relationship between basic characteristic (age, menstrual status, family history, reproductive history, pathological type, estrogen receptor [ER] status, progesterone receptor [PR] status, human epidermal growth factor receptor 2 [HER2] status, Ki-67 percentage, and molecular subtype), and metastasis sites (lung metastasis, liver metastasis, and bone metastasis) was examined by Pearson Chi-square tests. A total of 468 patients with de novo stage IV breast cancer were enrolled. The median age of the enrolled pat...Continue Reading
References
Mar 15, 2001·The New England Journal of Medicine·D J SlamonL Norton
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Lisa A CareyRobert C Millikan
May 3, 2008·Cancer Research·Marcel SmidJohn W M Martens
Apr 29, 2009·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·J RuiterkampA C Voogd
Jun 6, 2009·The Breast Journal·Atilla SoranBahadir M Gulluoglu
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K David VoducHagen Kennecke
Mar 12, 2010·Journal of the National Cancer Institute·Olivia PaganiUNKNOWN ESO-MBC Task Force
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagen KenneckeKaren Gelmon
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F CardosoUNKNOWN ESMO Guidelines Working Group
Jan 12, 2013·Annals of Surgical Oncology·Julie E LangGildy V Babiera
Apr 25, 2014·Journal of Surgical Oncology·Seema Ahsan Khan
May 30, 2014·The Lancet Oncology·Lei FanPaul E Goss
Jan 30, 2015·Clinical & Experimental Metastasis·L GerratanaF Puglisi
Mar 18, 2015·American Journal of Clinical Pathology·Abha SoniShi Wei
Mar 19, 2015·Breast Cancer Research and Treatment·Karin KastPauline Wimberger
Aug 5, 2015·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·C CriscitielloM Santangelo
Sep 14, 2015·The Lancet Oncology·Rajendra BadweSudeep Gupta
Oct 30, 2015·CA: a Cancer Journal for Clinicians·Carol E DeSantisAhmedin Jemal
Dec 3, 2015·JAMA Surgery·Alexandra ThomasMary C Schroeder
Mar 24, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tari A KingClifford A Hudis
Oct 9, 2016·Clinical & Experimental Metastasis·Anne Gulbech OrdingHenrik Toft Sørensen
Dec 16, 2016·Breast Cancer Research and Treatment·Bernardo Amadeo LeoneJosé Pablo Leone
Mar 16, 2017·CA: a Cancer Journal for Clinicians·Armando E GiulianoGabriel N Hortobagyi
Apr 22, 2017·Oncotarget·Qi WuShengrong Sun
Jan 10, 2018·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
May 20, 2018·Annals of Surgical Oncology·Atilla SoranRonald Johnson
Mar 8, 2019·Breast Cancer Research : BCR·Mohammad A AlzubiJ Chuck Harrell